title: Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.
abstract: This commentary highlights the article by Ge et al, which proposes the use of methylation and expression of SRD5A2 as a gene signature to tailor therapies for prostatic diseases.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Brady Urologic Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: isaacjo@jhmi.edu.
authors.forename: John T
authors.initials: JT
authors.lastname: Isaacs
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism*; D000375:Aging / Q000378:metabolism*; D000818:Animals; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000378:metabolism*; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D011467:Prostate / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism*
chemical_list: D008565:Membrane Proteins; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D004248:DNA (Cytosine-5-)-Methyltransferases